Key highlights
- Primary endpoint of non-inferiority in mean change in BCVA versus aflibercept control was not achieved
- Trial demonstrated a 38% reduction in treatment burden with a nominal p-value under 0.0001
- Fifty-two percent of study eyes remained supplement-free through the 56-week clinical period
- Approximately 71% of patients required zero or one supplemental injection throughout the trial
- Existing cash reserves of $180 million are projected to fund company operations into Q4 2027
What Happened
EyePoint reported that the LUCIA trial, evaluating DURAVYU for wet age-related macular degeneration, did not meet the primary endpoint of statistical non-inferiority in visual acuity compared to the aflibercept control group. While the drug demonstrated visual improvement, it failed to match the established standard of care in the primary efficacy metric. However, DURAVYU showed success in secondary metrics, specifically in reducing treatment burden. The data indicated that 52% of treated eyes remained supplement-free through Week 56, and 71% of participants required only zero or one supplemental injection during the study period.
Significance and Pipeline Strategy
This outcome represents a significant clinical hurdle as it is the second Phase 3 failure for DURAVYU in the wet AMD indication, following results from the LUGANO trial. Consequently, the company is re-evaluating its clinical strategy for wet AMD while shifting primary focus toward its ongoing Diabetic Macular Edema program. Management indicated that the multifactorial and inflammatory nature of DME might be better suited for the therapeutic profile of DURAVYU. The company intends to complete additional analyses of the pooled Phase 3 data to determine if a viable regulatory path remains for the wet AMD indication.
Business and Financial Context
- EyePoint utilizes proprietary Durasert E technology for sustained-release drug delivery into the eye
- Phase 3 DME program remains on track with topline data from COMO and CAPRI trials expected in Q4 2027
- Company maintains $180 million in cash and marketable securities to support operations into late 2027
- Third quarter 2026 financial results are scheduled for release on November 4, 2026
- Clinical focus remains on reducing the frequency of invasive intravitreal injections for retinal diseases
Down 89.7% since our story on 19 Oct: $2.99 when we broke it → $0.31 at the close on 16 Nov. Daily closing prices. Source: Yahoo Finance.
Show the prices
| 19 Oct | $0.44 |
|---|---|
| 20 Oct | $0.41 |
| 21 Oct | $0.43 |
| 22 Oct | $0.43 |
| 23 Oct | $0.40 |
| 26 Oct | $0.37 |
| 27 Oct | $0.36 |
| 28 Oct | $0.38 |
| 29 Oct | $0.38 |
| 30 Oct | $0.35 |
| 2 Nov | $0.37 |
| 3 Nov | $0.40 |
| 4 Nov | $0.40 |
| 5 Nov | $0.36 |
| 6 Nov | $0.36 |
| 9 Nov | $0.36 |
| 10 Nov | $0.40 |
| 11 Nov | $0.36 |
| 12 Nov | $0.32 |
| 13 Nov | $0.31 |
| 16 Nov | $0.31 |
Management Perspective
“We are disappointed that the LUCIA trial did not meet the primary endpoint given the promising scientific rationale of DURAVYU and its potential to improve outcomes for patients with wet AMD.”
Management commentary
“We are disappointed that the LUCIA trial did not meet the primary endpoint given the promising scientific rationale of DURAVYU and its potential to improve outcomes for patients with wet AMD.”
| Share price | $2.99 |
|---|---|
| Market cap | $258M |
| Revenue (annual) | $31M |
| 1-month price change | -13.33% |
| Sector | HealthcareBiotechnology |
Reference market data from a third-party provider, as of the story. Not a valuation or a recommendation.
SEC filing by EyePoint, Inc. announcing topline results from its LUCIA Phase 3 clinical trial.
Track EyePoint, Inc. live
Get the next EyePoint, Inc. SEC filing seconds after it lands.